SecBot SecBot
6-K ·Filed Nov 13, 2026

IMCC

IM Cannabis Corp.
BEARISH
Impact 6/10
Horizonweeks Processed3d 22h ago SEC0001178913-26-005212
6-K: Earnings release
Actionable Insight ▼ Bearish

The company's survival depends on its ability to raise additional capital and generate positive cash flow from its now Israel-only operations. Watch for the outcome of the proposed SDI acquisition and any further dilutive financings. The November 2026 convertible note provides near-term liquidity but adds significant potential dilution.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

IM Cannabis Corp. reported Q3 2026 revenue from continuing operations of $1.65M, down 68% YoY from $5.08M, and a gross loss of $0.04M vs. a $1.58M gross profit a year ago. Net loss widened to $7.08M from $3.87M. The company completed the sale of its European operations (IMC Holdings) on September 29, 2026, recognized a $2.7M gain, and now operates solely in the Israeli medical cannabis market. The MD&A discloses substantial doubt about going concern, with negative working capital of $5.5M and an accumulated deficit of $284.1M as of September 30, 2026.

Key Financial Metrics

EPS
−$6.69
Revenue
$1.6M
-67.5% YoY
Gross Margin
-2.12%

Key Facts

  • Q3 2026 revenue from continuing operations was $1.65M, down 68% from $5.08M in Q3 2025.
  • Q3 2026 gross loss from continuing operations was $0.04M, vs. gross profit of $1.58M in Q3 2025.
  • Q3 2026 net loss was $7.08M ($6.69 per share), vs. net loss of $3.87M ($0.44 per share) in Q3 2025.
  • Nine-month 2026 revenue from continuing operations was $8.96M, down 43% from $15.77M in the prior year.
  • Nine-month 2026 net loss from continuing operations was $10.83M, vs. $2.59M in the prior year.
  • Cash and restricted cash totaled $2.4M as of September 30, 2026, vs. $2.7M at December 31, 2025.
  • Working capital deficit was $5.5M as of September 30, 2026.
  • The MD&A states substantial doubt about the company's ability to continue as a going concern.
  • On September 29, 2026, the company completed the sale of IMC Holdings (European operations) for $3.0M in advance payments and assumption of up to $9.4M in liabilities, recognizing a $2.7M gain.
  • On November 4, 2026, the company closed a $1.2M convertible note financing with an institutional investor.

Financial Impact

Q3 2026 revenue declined 68% YoY to $1.65M; net loss widened to $7.08M from $3.87M; cash burn continues with $2.4M cash on hand and a $5.5M working capital deficit.

revenuenet losscashworking capital

Risk Factors

  • Going concern risk: substantial doubt about ability to continue as a going concern, with negative working capital and ongoing operating losses.
  • Dilution risk: multiple convertible notes and warrants outstanding, including the November 2026 note convertible into up to 3.9M shares at $0.61.
  • Nasdaq delisting risk: the stock has traded below $1.00 and the company has already used a reverse split within the past year, limiting cure options.
  • Concentration risk: the company now operates only in the Israeli medical cannabis market, exposed to geopolitical and regulatory risks.
  • Related-party transaction risk: CEO Oren Shuster is counterparty to the Slil transaction and the October 2026 debt settlement.

Market Snapshot

Exchange
Nasdaq
Sector
Medicinal Chemicals & Botanical Products
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 10 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001178913-26-005212
Exhibit: exhibit_99-2.htm0001178913-26-005212
Exhibit: exhibit_99-1.htm0001178913-26-005212
Exhibit: exhibit_99-5.htm0001178913-26-005212
Exhibit: exhibit_99-4.htm0001178913-26-005212
Document: zk2636388.htm0001178913-26-005212
Document: 0001178913-26-005212-index-headers.html0001178913-26-005212
Document: 0001178913-26-005212-index.html0001178913-26-005212
Document: 0001178913-26-005212.txt0001178913-26-005212
Earnings Context (Synthetic; results releases only)0001178913-26-005212

Track record

23 reports on IMCC

Performance horizon

9 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +82.97% at T+60 after the Aug 13, 2026 report. 11 of 11 went positive at some point.

Filters
  1. Nov 17, 2026today SC 13G Neutral 4/10 Entry $0.4995 Now $0.4800 −3.90% settles Dec 16
  2. Nov 13, 20263d ago 6-K Bearish 6/10 Viewing Entry price pending
  3. Nov 13, 20263d ago Press Release Bearish 6/10 Entry $0.5750 Now $0.4800 +16.52% settles Dec 15
  4. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5800 Now $0.4800 −17.24% settles Dec 15
  5. Nov 4, 202612d ago 6-K Bearish 6/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
  6. Nov 4, 202612d ago Press Release Bearish 5/10 Entry $0.5934 Now $0.4800 +19.11% settles Dec 4
  7. Oct 21, 202627d ago EFFECT Neutral 4/10 Entry $1.19 Now $0.4800 −59.66% settles Nov 18
  8. Oct 2, 20266w ago 6-K Mixed 6/10 Entry $1.94 to $0.7675 Now $0.4800 −75.26% ▼ −60.44% −57.86% vs SPY
  9. Sep 25, 20267w ago 6-K Bearish 6/10 Entry $2.48 to $0.8400 Now $0.4800 +80.65% ▲ +66.13% +66.10% vs SPY
  10. Sep 24, 20267w ago 424B5 Bearish 7/10 Entry $3.18 to $0.9250 Now $0.4800 +84.91% ▲ +70.91% +70.49% vs SPY
Showing 10 of 23

US Market Status

Market Open · Closes in 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026